866-945-0263 | enquiries@arrowheadpublishers.com

Life Science Market Research Reports

The Global Pain Therapeutics Market, 5th Edition: Market Trends & R&D Insights

Pain continues to represent major clinical, social and economic challenges. Globally, 1.5 billion people suffer from moderate to severe chronic pain. Pain is the leading cause of disability in the US, affecting 116 million adults, more than heart disease, cancer and diabetes combined. The US annual cost of chronic pain ranges from a colossal $560 to $635 billion.


Publication Date: December 12, 2015

Pages: 536

Regular Pricing: Single-User License: $3500

Company-Wide License: $7500

 

REQUEST SAMPLE PAGES


Despite two decades of intensive R&D effort, commercialization of new products has been limited. Current analgesics only provide modest pain relief, frequently carry black box safety warnings and are susceptible to abuse. Indeed, in the US, opioid abuse is described as a deadly epidemic.

In recent years, key blockbuster products OxyContin, Cymbalta, Celebrex and Lidoderm have faced patent loss. With Pfizer’s Lyrica patent expiry looming in 2018, the pain market will suffer further generic threat. Nevertheless, the hotly anticipated arrival of novel abuse-deterrent opioids and monoclonal antibodies such as NGF, CGRP and IL-6 inhibitors will drive future market growth.

This in-depth, quality report delivers:

• Analysis of seven major painful conditions examining epidemiology in the seven major markets, therapeutic management overview, unmet needs and clinical/commercial pipeline analysis of each condition to maximize your product’s commercial success

• Identification of the major challenges within pain R&D including unmet needs, clinical trial design, alternative R&D approaches, potential pain biomarkers, animal pain models, functional imaging techniques and regulatory hurdles

• An assessment of the financial pain market with forecasts to 2020 for over 70 leading branded analgesic products and key pipeline candidates

Report highlights:

The pain therapeutics market is crowded and heavily genericized. In 2015, the leading branded pain therapeutics market is worth $11.3 billion, down 13.5% from 2014 total revenues of $13.1 billion.

Opioids form the backbone of pain management. This trend is set to continue over the coming years thanks to their continued superior analgesic activity. Physicians should become increasingly more confident in prescribing opioids due the arrival of abuse-deterrent formulations. By 2020, the leading branded opioids will generate over $6.6 billion in worldwide revenues.

Pain R&D is challenging, expensive and reliant on subjective outcome measures. Therefore, industry must revise their R&D strategies to gain success in this market. The FDA's 2014 Draft Guidance for Industry Analgesic Indications: Developing Drug and Biological Products should provide some clarity for pain developers, as this was indeed the first guidance update in over 20 years.

Purchase of Arrowhead’s Global Pain Therapeutics Market, 5th Edition: Market Trends and R&D Insights 2015 will enable you to:

• Assess opportunities and challenges influencing strategic pain R&D

• Identify leading branded pain therapeutics and key pipeline candidates in late-stage development based on sales forecasts to 2020 to maximize your products commercial potential

• Gain an impartial perspective of strategies that can be used to enhance your products performance in the pain market

 
Key questions answered by Arrowhead’s Global Pain Therapeutics Market, 5th Edition: Market Trends and R&D Insights 2015 include:
 
• What are the major unmet needs in the current pain market?
• What are the leading potential pain biomarkers?
• What are the major challenges involved in the pain market and how can they be overcome?
• Who are the key players involved in the pain market and what business models are they using to raise company performance?
• How can players optimize strategic pain R&D to maximize commercial success?
• What recommendations does Arrowhead provide for successful pain R&D?
• What are the leading branded pain therapeutics available on the market?
• What are the key leading therapeutic candidates in the pain pipeline?
• How much revenue will the leading branded analgesic products reach by 2020?
• How much revenue will the key pipeline drug candidates reach by 2020?
• What does the future hold for the pain market?
 

Table of Contents

 
1          EXECUTIVE SUMMARY
1.1       Scope of Global Pain Therapeutics Market, 5th Edition
1.2       Methodology of Global Pain Therapeutics Market, 5th Edition
1.3       The Epidemiology of Pain in the Seven Major Markets
1.4       Unmet Needs in the Pain Therapeutics Market
1.5       Pain Therapeutics Pipeline Analysis
1.6       Pain Therapeutics Market Analysis
 
2          PAIN: DISEASE BACKGROUND
2.1       An Introduction to Pain
2.2       The Classification of Pain
2.2.1    Acute Pain
2.2.2    Chronic Pain
2.3       The Pathophysiology of Pain
2.3.1    The Pain Pathway
2.3.2    The Modulation of the Pain Signal
2.3.3    Referred Pain
2.4       The Immune System and Pain
2.4.1    Nerve Growth Factor (NGF)
2.4.2    Brain Derived Neurotrophic Factor (BDNF)
2.4.3    Nitrous Oxide (NO)
2.4.4    Tumor Necrosis Factor (TNF)
2.4.5    Interleukin-1 (IL-1)
2.4.6    Interleukin-6 (IL-6)
2.4.7    Glutamate
2.5       Pain and Genetics
2.6       The Subjective Nature of Pain
2.6.1    The Evaluation of Pain
2.7       The Global Impact of Pain
2.7.1    The Financial Impact of Pain
 
3          MANAGING PAIN: WHO’S PAIN THERAPEUTICS CLASSES AND TREATMENT GUIDELINES
3.1       Overview of the WHO’S Pain Therapeutics Classification
3.2       M01A Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
3.3       M01B Anti-Inflammatory/Anti-Rheumatic Agents in Combination
3.4       N01A General Anesthetics
3.5       N01B Local Anesthetics
3.6       N02A Narcotic Analgesics
3.7       N02B Non-Narcotic Analgesics
3.8       N02C Anti-Migraine Preparations
3.9       Arrowhead’s Analgesic Drug Classification System
3.10    WHO Pain Management Guidelines
 
4          THE POSTOPERATIVE PAIN MARKET
4.1       Overview of Postoperative Pain
4.2       Epidemiology of Postoperative Pain
4.3       The Therapeutic Management of Postoperative Pain
4.3.1    Epidural Local Anesthetics Used in Postoperative Pain
4.3.2    Strong Opioids Used in Postoperative Pain
4.3.3    Weak Opioids Used in Postoperative Pain
4.3.4    NSAIDs Used in Postoperative Pain
4.3.5    Multi-Modal Analgesia Used in Postoperative Pain
4.4       Leading Brand Products in the Postoperative Pain Market
4.4.1    Janssen Pharmaceuticals’ Duragesic (transdermal fentanyl)
4.4.2    Pacira Pharma’s Exparel (bupivacaine liposome injection)
4.4.3    Hospira Inc’s Dyloject (Dicofenac Injection)
4.5       Unmet Needs in the Postoperative Pain Market
4.6       Postoperative Pain Therapeutics Pipeline Analysis
4.6.1    Durect Corporation’s Posidur (SABER-bupivacaine)
4.6.2    Trevena’s TRV130
4.6.3    Adynxx’s AYX1
4.6.4    Yichang Humanwell’s Morphine 6-gluconaride (M6G, intravenous morphine)
4.7       Postoperative Pain Therapeutics Market Commentary
 
5          THE NEUROPATHIC PAIN MARKET
5.1       Overview of Neuropathic Pain
5.2       Epidemiology of Neuropathic Pain
5.3       The Therapeutic Management of Neuropathic Pain
5.3.1    Topical Lidocaine Used in Neuropathic Pain
5.3.2    Antidepressants Used in Neuropathic Pain
5.3.3    Opioids Used in Neuropathic Pain
5.4       Leading Brand Products in the Neuropathic Pain Market
5.4.1    Endo Pharmaceuticals’ Lidoderm (lidocaine 5% Patch)
5.4.2    Pfizer’s Lyrica (pregablin)
5.4.3    Eli Lilly’s Cymbalta (duloxetine)
5.4.4    Pfizer’s Neurontin (gabapentin)
5.4.5    Johnson&Johnson/Depomed’s Nucynta ER (tapentadol-er)
5.4.6    Acorda Therapeutics/Astellas Pharma’s Qutenza (capsaicin 8% patch)
5.4.7    Depomed/Abbott’s Gralise (gabapentin-er)
5.5       Unmet Needs in the Neuropathic Pain Market
5.6       Neuropathic Pain Therapeutics Pipeline Analysis
5.6.1    BioDelivery Sciences International’s Topical Clonidine Gel
5.6.2    Daiichi Sankyo’s Mirogabalin (DS-5565)
5.6.3    Immune Pharmaceuticals’ AmiKet (amitriptyline/ketamine)
5.6.4    Biogen’s CNV-1014802
5.6.5    Impax Laboratories/Durect Corps’s Eladur (Transdur-Bupivacaine Patch)
5.6.6    Convergence Pharmaceuticals/Calchan’s CNV-2197944
5.6.7    Novartis/Spinifex Pharmaceuticals’EMA401
5.6.8    Pfizer’s Lyrica-CR (pregabalin controlled-release)
5.7       Neuropathic Pain Therapeutics Market Commentary
 
6          THE FIBROMYALGIA MARKET
6.1       Fibromyalgia Overview
6.2       Epidemiology of Fibromyalgia
6.3       The Therapeutic Management of Fibromyalgia Pain
6.3.1    Analgesics Used in Fibromyalgia
6.3.2    Antidepressants Used in Fibromyalgia
6.3.3    Muscle Relaxants Used in Fibromyalgia
6.3.4    Sleep Modifiers Used in Fibromyalgia
6.3.5    Anxiety Medications Used in Fibromyalgia
6.3.6    Anticonvulsants Used in Fibromyalgia
6.3.7    Antibiotics Used in Fibromyalgia
6.4       Leading Brands in the Fibromyalgia Pain Market
6.4.1    Pfizer’s Lyrica (pregabalin)
6.4.2    Allergen/Forest Laboratories ‘Savella (milnacipran)
6.4.3    Eli Lilly’s Cymbalta (duloxetine)
6.5       Unmet Needs in Fibromyalgia Pain Market
6.6       Fibromyalgia Pain Pipeline Analysis
6.6.1    Daiichi Sankyo’s Mirogabalin (DS-5565)
6.6.2    Tonix Pharmaceuticals’ TNX-102 SL
6.6.3    Theravance Biopharmas’ TD-9855
6.6.4    Pfizer’s Lyrica-CR (pregablin controlled-release)
6.7       Fibromyalgia Pain Market Commentary
 
7          THE ARTHRITIC PAIN MARKET
7.1       Arthritis Overview
7.2       Epidemiology of Arthritic Pain
7.3       The Therapeutic Management of Arthritic Pain
7.3.1    Acetaminophen used in Arthritis
7.3.2    NSAIDs Used in Arthritis
7.3.3    COX-2 Inhibitors Used in Arthritis
7.3.4    Disease Modifying Anti-Rheumatic Drugs (DMARDs) Used in Arthritis
7.3.5    Biologic Disease Modifying Anti-inflammatory Drugs Used in Arthritis
7.3.6    Corticosteroids Used in Arthritis
7.3.7    Immunosuppressants used in Arthritis
7.4       Leading Brands in the Arthritic Pain Market
7.4.1    Horizon Pharma/AstraZeneca/Pozen ’s Vimovo (naproxen/esomeprazole)
7.4.2    Pfizer Celebrex (celecoxib) 
7.4.3    Pfizer’s Arthrotec (diclofenac/misprostol)           
7.4.4    Boehringer Ingelheim/Abbott’s Mobic (meloxicam)
7.4.5    Pfizer’s DayPro (oxarprozin)
7.4.6    Pfizer’s Xeljanz (tofacitinib)
7.5       Unmet Needs in the Arthritic Pain Market
7.6       Arthritic Pain Therapeutic Pipeline Analysis
7.6.1    Eli Lilly/Incyte’s Baricitinib
7.6.2    Galapagos NV/AbbVie’s Filgotinib (GLPG0634)   
7.6.3    Astellas’Peficitinib (ASP015K)
7.6.4    Sanofi/Regeneron’s Sarilumab (REGN88/SAR153191)
7.6.5    Janssen/GSK’s Sirukumab (CNTO136)
7.6.6    Alder Biopharmaceuticals’ Clazakizumab
7.6.7    Epirus Biopharmaceuticals’ BOW015 (infliximab)
7.7       Arthritic Pain Market Commentary
 
8          THE MIGRAINE MARKET
8.1       Migraine Overview
8.2       Epidemiology of Migraine
8.3       The Therapeutic Management of Migraine
8.3.1    Prophylactic Migraine Therapies
8.3.2    Basic Analgesics Used in Migraine
8.3.3    Ergot Alkaloid Derivatives Used in Migraine
8.3.4    Triptans Used in Migraine
8.3.5    Neuroleptics Used in Migraine
8.3.6    Beta-Blockers Used in Migraine
8.4       Leading Brand Products in the Migraine Market
8.4.1    GSK’s Imitrex/Imigran (sumatriptan)
8.5       Impax Laboratories/AstraZeneca’s Zomig (zolmitriptan)
8.5.1    Merck’s Maxalt (rizartriptan)
8.5.2    Pfizer’s Relpax (eletriptan)
8.5.3    Pernix Therapeutics/Pozen’s Treximet (sumatripatan/naproxen)
8.5.4    Janssen’s Topamax (topiramate)
8.5.5    AbbVie’s Depakote (divalproex)
8.5.6    Allergan’s Botox (onabotulinumtoxinA)
8.6       Unmet Needs in the Migraine Market
8.7       Migraine Therapeutics Pipeline Analysis
8.7.1    CoLucid Pharmaceuticals’ Lasmiditan (COL-144)
8.7.2    Allergens’ Semprana (dihydroergotamine)
8.7.3    Avanir/OptiNose’s AVP-825 (sumatriptan intranasal powder)
8.7.4    Trigemina’s T1-001 (oxytocin)
8.7.5    Alder Biopharmaceuticals’ ALD403
8.7.6    Amgen’s AMG 334
8.7.7    Teva Pharmaceuticals’ TEV-48125
8.7.8    Eli Lilly’s LY2951742
8.8       Migraine Market Commentary
 
9          THE CANCER PAIN MARKET
9.1       Cancer Pain Overview
9.2       Epidemiology of Cancer Pain
9.3       The Therapeutic Management of Cancer Pain
9.3.1    Strong Opioids Used in Cancer Pain
9.3.2    Weak Opioids Used in Cancer Pain
9.3.3    NSAIDs and Acetaminophen Used in Cancer Pain
9.3.4    Adjuvants Used in Cancer Pain
9.4       Leading Brands in the Cancer Pain Market
9.4.1    Teva’s Actiq (oral transmucosal fentanyl citrate)
9.4.2    Teva’s Fentora (fentanyl buccal)
9.4.3    Purdue’s OxyContin (oxycodone)
9.4.4    Galena Biopharma/ProStrakan’s Abstral (fentanyl sublingual)
9.4.5    Insys Therapeutics’ Subsys (sublingual fentanyl)
9.5       Unmet Needs in the Cancer Pain Therapeutics Market
9.6       Cancer Pain Therapeutics Pipeline Analysis
9.6.1    GW Pharmaceuticals’ Sativex (GW-1000)
9.6.2    Wex Pharmaceuticals’ Tectin (tetrodotoxin)
9.6.3    AcelRX Pharmaceuticals’ ARX-02   
9.7       Cancer Pain Therapeutics Market Commentary
 
10       THE BACK PAIN MARKET   
10.1    Back Pain Overview
10.2    Epidemiology of Back Pain
10.3    The Therapeutic Management of Back Pain         
10.3.1 NSAIDs Used in Back Pain
10.3.2 Transdermal Patches Used in Back Pain   
10.3.3 Local Anesthetics Used in Back Pain
10.3.4 Opioids Used in Back Pain  
10.3.5 Tricyclic Antidepressants Used in Back Pain
10.3.6 Muscle Relaxants Used in Back Pain
10.3.7 Colchicine Used in Back Pain
10.3.8 Anticonvulsants Used in Back Pain
10.4    Leading Brand Products in the Back Pain Market
10.4.1 Bayer’s Aleve (naproxone)
10.4.2 Novartis’ Voltaren (diclofenac)
10.4.3 Pfizer’s Advil (ibuprofen)
10.4.4 BMS’ Efferalgan (acetaminophen)
10.4.5 Johnson &Johnson’s Tyenol (acetaminophen)
10.5    Unmet Needs in the Back Pain Market
10.6    Back Pain Pipeline Analysis
10.6.1 Pfizer’s Tanezumab
10.6.2 Pfizer’s ALO-02(oxycodone-naltrexone)
10.6.3 Teva Pharmaceuticals’ CEP-33237 (Hydrocodone ER-Abuse Deterrent)
10.6.4 Collegium Pharmaceuticals’ Xtampza ER (Oxycodone ER)
10.6.5 Mesoblast’s MPC-016 –ID
10.7    Back Pain Market Commentary
 
11       PAIN THERAPEUTICS RESEARCH AND DEVELOPMENT TRENDS
11.1    Introduction to Pain R&D: The Need for Change
11.2    Overview of Clinical Trials
11.2.1 The Triad of Successful Pain Clinical Trials
11.3    Issues Surrounding Analgesic Clinical Trials
11.3.1 Patient Selection
11.3.2 Randomization, Stratification and Blinding
11.3.3 Trial Duration           
11.3.4 Trial Comparator Drug Choice
11.3.5 Trial Endpoint Choice
11.3.1 Patient Dropout
11.3.2 Missing Data 
11.3.3 Placebo Effect
11.4    Biomarkers in R&D
11.4.1 Predictive Biomarkers as Clinical Trial Surrogate Endpoints
11.4.2 The Use of Biomarkers to Stratify Patients
11.4.3 Potential Pain Biomarkers
11.4.4 Personalized Medicine in Pain
11.5    Analgesic Target Selection and Validation
11.6    Animal Pain Models
11.7    Experimental Pain Models in Healthy Humans
11.7.1 UV-B Pain Model
11.7.2 Heat/Capsaicin Sensitization and Intradermal Capsaicin Injection Models
11.7.3 Multi-Modal, Multi-Tissue Model
11.7.4 Quantitative Sensory Testing
11.8    Functional Imaging Techniques
11.8.1 Functional Magnetic Resonance Imaging (fMRI)
11.8.2 Positron Emission Tomography (PET)
11.8.3 Single-Photon Emission Computed Tomography (SPECT)
11.9    Laser Doppler Flowmetry (LDF)
11.9.1 US Health Agencies Findings and Recommendations for Change in Pain R&D
11.9.2 Arrowhead’s Recommendations for Maximizing Pain Therapeutics R&D
11.9.3 The Future of Pain R&D
11.10  FDA’s Efforts to Combat Opioid Misuse and Abuse
11.10.1           Abuse-Deterrent Formulations
11.10.2           Abuse Liability and Safety/ Risk Evaluation and Mitigation Strategy (REMS)
 
12       UNMET NEEDS IN THE PAIN THERAPEUTICS MARKET
12.1    Clinical Efficacy Of Today’s Analgesics Need Improving
12.2    Safety Profiles of Current Pain Therapeutics Are Often Unacceptable
12.3    Opioid Misuse and Abuse
12.4    Certain Pain Patient Populations are Neglected
12.5    Improved Dosing Regimens
12.6    Convenient Administration Routes
12.7    The Validity of Animal Pain Models
12.8    The Reliability of Pain Evaluation Models
12.8.1 Lack of Stakeholder Education
 
13       PAIN THERAPEUTICS PIPELINE WATCH
13.1    Introduction to the Pain Therapeutics Pipeline   
13.2    Targeted Therapies
13.2.1 Pfizer’s Tanezumab (PF-4383119)
13.2.2 Janssen’s Fulranumab
13.3    Nav Ion Channel Modulators
13.3.1 Convergence Pharmaceuticals’ CNV1014802
13.3.2 Xenon/Teva’s TV-45070
13.3.3 Nektar’s NKTR-171
13.3.4 Xenon/Genentech’s GDC-0276
13.3.5 Pfizer’s NAV1.7/1.8 Inhibitors
13.4    Transient Receptor Potential (TPR) Channel Modulators
13.4.1 TRPV1 Agonists
13.4.2 Sorrento Therapeutics’ Resiniferatoxn (RTX)
13.4.3 TRP Antagonists
13.5    Purinoreceptor (P2X3 Receptor) Antagonists
13.5.1 Afferent Pharmaceuticals P2X3 Program 
13.6    Glutumate Receptor Antagonists
13.6.1 NMDA-Receptor Antagonists
13.6.2 NDMA and Opioid Receptor Overlap
13.6.3 Dual Mu-Opioid Agonist and Nor Epinephrine Reuptake Inhibitors
13.7    Imidazoline l2 Receptors
13.8    Abuse-Deterrent Opioids
13.8.1 Collegium Pharmaceuticals’ Xtampza ER (oxycodone DETERx)
13.8.2 Pfizer’s ALO-02 (oxycodone/naltrexone)
13.8.3 Teva Pharmaceuticals’ CEP-33237 (Hydrocodone ER)  
13.8.4 Microglia Inhibitors
 
14       ANALYSIS OF THE PAIN THERAPEUTIC MARKET
14.1    Summary of Arrowhead’s Pain Therapeutics Analysis, 2015
14.2    Leading Pain Therapeutic Products of 2014
14.3    Leading Pain Therapeutics Drug Classes of 2014
14.4    Leading Pain Therapeutics Drug Class Products of 2014
14.4.1 COX-2 Inhibitors: Pfizer’s Celebrex (celecoxib)
14.4.2 NSAIDs: Novartis’ Voltaren (diclofenac)
14.4.3 Local Anesthetics: Pacira’s Exparel (bupivacaine liposome Injection)
14.4.4 Opioids: Purdue’s OxyContin (oxycodone)
14.4.5 Triptans: Pfizer’s Relpax (eletriptan)
14.4.6 Non-traditional: Pfizer’s Lyrica (pregabalin)
14.5    Pfizer: Arrowhead’s Leading Pain Therapeutics Company of 2014/2015
14.6    SWOT Analysis of the Pain Therapeutics Market, 2015
14.7    Financial Forecast of the Pain Therapeutics Market
14.7.1 Financial Forecast of the Branded Pain Therapeutic Market
14.8    Arrowhead’s NSAID Market Outlook
14.8.1 Drivers and Constraints of the NSAID Market
14.8.2 Financial Forecast of the NSAID Market
14.9    Arrowhead’s Cox-2 Market Outlook
14.9.1 Drivers and Constraints of the COX-2 Market
14.9.2 Financial Forecast of the COX-2 Market ($m)
14.10  Arrowhead’s Opioid Market Outlook         
14.10.1           Drivers and Constraints of the Opioid Market
14.10.2           Financial Forecast of the Opioid Market
14.10.3           Arrowhead’s Triptan Market Outlook
14.10.4           Drivers and Constraints of the Triptan Market
14.10.5           Financial Forecast of the Triptan Market
14.10.6           Arrowhead’s Non-Traditional/Adjuvant Market Outlook           
14.10.7           Drivers and Constraints of the Non-Traditional/Adjuvant Pain Therapeutic Market
14.10.8           Financial Forecast of the Non-Traditional/Adjuvant Market
14.11  Arrowhead’s Local Anesthetics Market Outlook
14.11.1           Drivers and Constraints of the Local Anesthetic Market
14.11.2           Financial Forecast of the Local Anesthetics Market
14.12  Summary of the Future Global Pain Therapeutic Market
 
15       COMPANY BRIEFS    
15.1    Abbvie Inc.
15.2    Acelrx Pharmaceuticals Inc.
15.3    Acorda Therapeutics Inc.
15.4    Adynxx
15.5    Alder Biopharmaceuticals Inc.
15.6    Allergan
15.7    Amgen Inc.
15.8    Astellas Pharmaceuticals Inc.
15.9    AstraZeneca
15.10  Avanir Pharmaceuticals Inc.
15.11  Biogen Inc.
15.12  Biosciences Delivery International Inc.
15.13  COLLEGIUM Pharmaceutical Inc.
15.14  Colucid Pharmaceuticals Inc.
15.15  Daiichi Sankyo Company Ltd.
15.16  Depomed Inc.
15.17  Durect Corporation
15.18  Eli Lilly and Company          
15.19  Endo Pharmaceuticals Inc.
15.20  Epirus Biopharmaceuticals
15.21  Galapagos NV
15.22  Galena Biopharma
15.23  GW Pharmaceuticals PLC
15.24  Horizon Pharma PLC
15.25  Hospira Inc.
15.26  Incyte Corporation
15.27  Immune Pharmaceuticals
15.28  Impax Laboratories
15.29  Insys Therapeutics Inc.
15.30  Johnson & Johnson
15.31  Meda AB
15.32  Mesoblast Ltd.
15.33  Novartis International AG
15.34  Optinose US Inc.
15.35  Pacira Pharmaceuticals Inc.
15.36  Pernix Therapeutics Holdings Inc.
15.37  Pfizer Inc.
15.38  Proove Biosciences Inc.
15.39  Pozen Inc.
15.40  Prostrakan Group
15.41  Purdue Pharmaceuticals LP
15.42  Regeneron Pharmaceuticals Inc.
15.43  Sanofi
15.44  Spinifex Pharmaceuticals Pty Ltd.
15.45  Teva Pharmaceuticals Industries Ltd.
15.46  Theravance Biopharma
15.47  Tonix Pharmaceuticals
15.48  Trevena Inc.
15.49  Trigemina Inc.
15.50  WEX Pharmaceuticals
15.51  Yichang Humanwell Pharmaceutical Co. Ltd.
 
16       BIBLIOGRAPHY
 
LIST OF TABLES
Table 1: Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Table 2: Current Preregistration Pain Therapeutics Pipeline, Oct 2015
Table 3: Comparison of the Global Pain Therapeutics Market ($m) Revenue by Analgesic Class, 2015 and 2020
Table 4: Characteristics and Treatment of Acute versus Chronic Pain
Table 5: Heritability Link in a Range of Diseases where Pain is a Predominant Factor
Table 6: Single Nucleotide Polymorphisms (SNPs) Suggested to Affect Human Pain Sensitivity
Table 7: Incidence of Pain Compared to Other Major Conditions in the US
Table 8: Incidence of Painful Conditions in US Households
Table 9: Ranking of the Global Leading Disability Conditions
Table 10: Annual Cost of Treating Back Pain by European Country
Table 11: WHO Guidelines for Pain Management
Table 12: Surgery Incidence Forecast in the Seven Major Markets, 2008-2020
Table 13: Postoperative Acute Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Table 14: Late-Stage and Phase II Postoperative Pain Therapeutics Pipeline, Oct 2015
Table 15: Common Etiologies Associated with Neuropathic Pain
Table 16: Neuropathic Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Table 17: Neuropathic Pain Therapeutics
Table 18: Summary of Branded Therapeutics FDA Approved for Neuropathic Pain
Table 19: Late-Stage and Phase II Neuropathic Pain Therapeutics Pipeline, Oct 2015
Table 20: Fibromyalgia Incidence Forecast in the Seven Major Markets, 2008-2020
Table 21: Late-Stage and Phase II Fibromyalgia Pain Therapeutics Pipeline, Oct 2015
Table 22: Arthritis Incidence Forecast in the Seven Major Markets, 2008-2020
Table 23: Late-Stage and Phase II Arthritic Pain Therapeutics Pipeline, Oct 2015
Table 24: Incidence Rate of Migraine (%) by Gender in the Seven Major Markets
Table 25: Migraine Incidence Forecast in the Seven Major Markets, 2008-2020
Table 26: Common Analgesics Used for Mild Migraine
Table 27: Ergot Alkaloid Derivatives Used for Migraine
Table 28: Triptans Used for Migraine
Table 29: Late-Stage and Phase Migraine Pain Therapeutics Pipeline, Oct 2015
Table 30: Crude Incidence Rate of Cancer by Gender in the Seven Major Markets
Table 31: Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Table 32: Cancer Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Table 33: The Oral and Paraental Equivalences and Relative Potency of Opioids Compared with Morphine
Table 34: Adjuvant Therapeutics Used in Cancer Pain Management
Table 35: Late-Stage and Phase II Cancer Pain Therapeutics Pipeline, Oct 2015
Table 35: Late-Stage and Phase II Cancer Pain Therapeutics Pipeline, Oct 2015
Table 36: Low Back Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Table 37: Late-Stage and Phase II Back Pain Therapeutics Pipeline, Oct 2015
Table 38: Potential Pain Biomarkers
Table 39: Pain Therapeutics Investigated by fMRI
Table 40: Pain Therapeutics Pipeline, Oct 2015
Table 41: Sodium Channel Modulators Pipeline, Oct 2015
Table 42: Summary of Branded Analgesics Analyzed by Arrowhead Publishers, 2015 Table 43: Top-10 Selling Branded Analgesics, 2014 Revenues ($m)
Table 44: Revenues of the 2014 and 2013 Top-Selling Analgesics by Drug Classification ($m)
Table 45: Global Leading Branded Pain Therapeutic Revenue History ($m), 2009-2014
Table 46: Summary of Arrowhead’s Key Pipeline Pain Therapeutics Candidates, 2015
Table 47: Global Leading Branded Pain Therapeutic Revenue Forecast ($m), 2015-2020
Table 48: Financial Forecast of the NSAID Global Market ($m), 2014-2020
Table 49: Financial Forecast of the COX-2 Global Market ($m), 2014-2020
Table 50: Financial Forecast of the Opioid Global Market ($m), 2014-2020
Table 51: Financial Forecast of the Triptan Global Market ($m), 2014-2020
Table 52: Financial Forecast of the Non-Traditional/Adjuvant Global Market ($m), 2014-2020
Table 53: Financial Forecast of Local Anesthetics Global Market ($m), 2014-2020
Table 54: Total Global Leading Branded Pain Therapeutic Market Forecast ($m) by Drug Class, 2014-2020
Table 55: Total Global Pain Therapeutics Market Revenue Forecast ($bn), 2014-2020
 
LIST OF FIGURES
Figure 1: Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 2: Pain Incidence Forecast in the Seven Major Markets, 2015 and 2020
Figure 3: Unmet Needs in the Pain Therapeutics Market
Figure 4: Analgesic Drug Class Share of the Global Pain Therapeutics Market, 2015
Figure 5: Analgesic Drug Class Share of the Global Pain Therapeutics Market, 2020
Figure 6: Schematic Diagram of the Pain Pathway
Figure 7: Schematic Diagram of Referred Pain Pathways Involved in an Ischemic Cardiac Attack
Figure 8: Examples of Pain Evaluation Models
Figure 9: Leading Causes of Pain in the US          
Figure 10: Surgery Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 11: Postoperative Acute Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 12: World Federation of Societies of Anesthesiologists (WFSA) Analgesic Ladder
Figure 13: PROSPECT Postoperative Pain Management Algorithm
Figure 14: TRV130’s Hypothesized Mode of Action compared with Morphine
Figure 15: Neuropathic Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 16: NIH Algorithm for Managing Neuropathic Pain
Figure 17: Fibromyalgia Painful Points within the Human Body           
Figure 18: Fibromyalgia Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 19: Treatment Algorithm for Fibromyalgia
Figure 20: Arthritis Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 21: Arthritis Therapeutic Treatment Algorithm
Figure 22: Migraine Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 23: European Federation of Neurological Societies (EFNS) 2009 Migraine Treatment Algorithm
Figure 24: CoLucid’s Lasmiditan Migraine Development Program Timeline
Figure 25: Cancer Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 26: Cancer Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 27: WHO’s Three-Step ‘Analgesia Ladder’ for Cancer Pain Management
Figure 28: Low Back Pain Incidence Forecast in the Seven Major Markets, 2008-2020
Figure 29: Back Pain Treatment Algorithm
Figure 30: The Triad of Successful Pain Clinical Trials
Figure 31: Schematic Diagram of Blood Oxygenation Level Dependent (BOLD) Concept in MRI
Figure 32: A Proposed New Analgesic Drug Development Pathway
Figure 33: Drug Overdose Related Deaths Involving Opioids in the US, 1999-2012 Figure 34: SWOT Analysis of the Pain Therapeutics Market, 2015
Figure 35: Global Leading Branded Pain Therapeutic Revenue Forecast ($m), 2009-2020
Figure 36: Financial Forecast of the NSAID Global Market ($m), 2014-2020
Figure 37: Financial Forecast of the COX-2 Global Market ($m), 2014-2020
Figure 38: Financial Forecast of the Opioid Global Market ($m), 2014-2020
Figure 39: Financial Forecast of the Triptan Global Market ($m), 2014-2020
Figure 40: Financial Forecast of the Non-Traditional/Adjuvant Global Market ($m), 2014-2020
Figure 41: Financial Forecast of Local Anesthetics Global Market ($m), 2009-2015
Figure 42: Total Global Leading Branded Pain Therapeutics Market Forecast ($m) by Drug Class, 2014-2020
Figure 43: Total Global Leading Branded Pain Therapeutics Market Revenue Forecast ($m), 2014-2020
Figure 44: Total Global Pain Therapeutics Market Revenue Forecast ($bn), 2014-2020

Contact Us

5780 Lincoln Drive, Suite 205
Edina, MN 55436 USA
866-945-0263
www.arrowheadpublishers.com
enquiries@arrowheadpublishers.com

Speaker Opportunities

If you are interested in speaking at one of Arrowhead's conferences or would like to suggest a conference theme for which you have particular expertise, we'd like to hear from you.

Sponsor/Exhibitor Opportunities

Arrowhead sponsorship and exhibitor levels are designed to give your organization the highest level of exposure and opportunity to market products and branding in an environment that is targeted toward facilitating professional networking. We can also build tailor-made packages that will meet your organization's marketing budget and goals. Arrowhead sponsorships are proven to help grow businesses through direct and targeted exposure to industry leaders and decision makers. To gain critical industry exposure via our sponsorship and exhibiting opportunities, please contact us.